Growth of the pharmaceutical consulting market in India is spurred by the rapid development of the pharmaceutical industry. India’s pharmaceutical sector, which is one of the largest global suppliers of generic drugs and vaccines, is set to reach $130 billion by 2030, creating a huge demand for consulting services that can bring strategic insights, regulatory compliance and operational efficiency. The key factors in this growth include the increasing complexity of global regulations, the emergence of more advanced technologies such as artificial intelligence and machine learning in drug development, and increasing pressure on cost optimization. To help pharmaceutical companies in navigating these challenges, consulting services like regulatory affairs, supply chain management, market access strategies and quality assurance are there to consult and assist in business.

The consulting sector has been further strengthened due to the efforts of India in becoming a hub for biosimilars and biopharmaceuticals. They need help on how to scale up production, how to get global regulatory approvals and how to optimize manufacturing. Furthermore, the government’s Production Linked Incentive (PLI) Scheme helps pharmaceutical companies gain more operational strength and opportunities for consulting partnerships. With the help of robust pharmaceutical consulting, firms pulled through the pandemic seeking help for accelerating clinical trials, managing disruptions and supply chains and expanding the digital health initiatives. As a result, there has been a boom in demand for digital transformation and risk management consultancy.

Keeping tabs on this market, India Pharma Outlook has shortlisted the select few companies in this field that have exhibited an unrelenting pursuit of excellence. By proving their dedication to fulfilling customer expectations and contributing to the market’s evolution through their innovative disposition, these firms are blazing a trail.

We look forward to receiving your feedback and suggestions.